en · de · es · pt
epitalon-notes.peptides7501.com › Guide › Epitalon Background And Discovery — Complete Guide

Epitalon Background And Discovery — Complete Guide

By Editorial Desk · published 2025-09-13 · last reviewed 2025-10-25 · Guide

epithalamin raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

This page was last updated on 2025-10-25 and is reviewed periodically as new material appears.

Epitalon Background and Discovery

The peptide emerged from research carried out in Saint Petersburg from the late 1980s onward, where investigators searched for shorter active fragments of a pineal preparation known as epithalamin. The name epitalon was chosen to reflect that parent extract. Early reports described effects on neuroendocrine markers and on the lifespan of laboratory animals. Much of that work appeared in Russian-language journals, with English translations following later, which affects how readily the original protocols can be assessed by outside groups.

Published studies on epitalon are dominated by a small number of research groups, and independent replication in other laboratories remains limited. Proposed mechanisms include activation of telomerase and modulation of melatonin rhythms, but the evidence for either rests mainly on cell cultures and animal models. Whether the peptide produces comparable effects in humans is an open question, and the absence of large controlled trials means the literature is best read as exploratory rather than settled.

Identity and Research Background

Epitalon is a synthetic tetrapeptide whose sequence is alanine–glutamate–aspartate–glycine, commonly abbreviated AEDG. It was developed in Russia during the 1980s and 1990s by investigators associated with the St. Petersburg Institute of Bioregulation and Gerontology, who studied short peptides as regulators of gene expression and tissue function. The alternative spelling epithalon appears interchangeably in the literature, and the two names refer to the same molecule. Outside Russia it is encountered chiefly as a research chemical rather than a licensed medicine, and it holds no approval from the United States Food and Drug Administration or the European Medicines Agency.

The peptide is a synthetic analogue of epithalamin, a preparation extracted from bovine pineal glands. Investigators sought a short, chemically defined molecule that would reproduce some of the endocrine and gerontological observations attributed to the glandular extract. Proposed mechanisms centre on induction of telomerase activity, an effect reported in cultured human somatic cells in the early 2000s, together with influences on melatonin secretion and neuroendocrine regulation. Those mechanisms remain incompletely characterised, and the reported telomerase response has not been consistently reproduced by independent groups working in comparable systems.

Epitalon at a glance

PropertyValueNotes
Molecular formulaC14H22N4O9Derived from the four-residue sequence
Molar massAbout 390.35 g/molFree peptide, counter-ion not included
AppearanceWhite to off-white powderLyophilised solid from aqueous solution
Water solubilityFreely solubleShort, polar peptide chain
Common synonymsAEDG; epithaloneCatalogues use the names interchangeably

Peptide Identity and Research Origin

Epitalon is a synthetic tetrapeptide with the sequence alanine–glutamate–aspartate–glycine, commonly abbreviated AEDG. Its design traces to epithalamin, a peptide fraction prepared from bovine pineal gland extracts that researchers in Saint Petersburg began investigating in the 1970s. The compound has a molecular formula of C14H22N4O9 and a nominal molecular mass near 390 daltons. It holds no approved drug status in the United States or the European Union, and material sold under this name is generally offered as a research chemical rather than a finished pharmaceutical product.

Proposed mechanisms centre on cell-culture observations rather than a defined receptor interaction. Several reports describe increased expression of the telomerase catalytic subunit after exposure of cultured human cells, and the authors attributed the effect to short peptide fragments entering the nucleus and influencing gene transcription. No receptor for the tetrapeptide has been identified, and the free peptide is expected to be degraded rapidly by plasma peptidases. Whether any measurable fraction reaches intact tissues after administration remains an unresolved question rather than an established finding.

The published literature is dominated by a small number of research groups, much of it in Russian-language journals, and independent replication outside those groups is limited. Studies are typically small, use cultured cells or rodent models, and report endpoints that differ between papers, which makes comparison difficult. Large randomised human trials have not appeared in the indexed literature. Questions about absorption, distribution and clearance are therefore still treated as open in reviews that mention the compound.

Related pages on this site

Epitalon Structure and Research Origin

Discussions in the literature often conflate three distinct entities: the pineal extract epithalamin, the isolated tetrapeptide AEDG, and commercial preparations sold under similar names. Reviews citing older Russian-language studies sometimes omit detail on purity, route of administration and control groups, which makes cross-study comparison difficult. Researchers working with the compound generally note the need for independent replication, standardized enzyme assays, and clearer reporting of peptide identity. These caveats are relevant when weighing claims that appear in secondary sources rather than in primary reports.

(TG:@pojiaai)Epitalon is a synthetic linear tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, abbreviated AEDG. It emerged from work on epithalamin, a peptide fraction prepared from bovine pineal tissue, and was designed as a short, chemically defined analogue of that extract. Early publications came mainly from Russian laboratories studying pineal peptides and aging-related endpoints. The compound appears in the literature under several spellings, including epithalon and epithalone, which complicates systematic searching. Its small size makes solid-phase assembly and routine analytical characterization straightforward.

Background and Chemical Identity

Epitalon is a synthetic linear tetrapeptide with the sequence alanine–glutamate–aspartate–glycine, abbreviated AEDG. Its molecular formula is C14H22N4O9 and the calculated mass is approximately 390.35 g/mol. The compound is made by solid-phase peptide synthesis rather than extracted from tissue, although early work described it as a short fragment of a peptide fraction obtained from bovine pineal extract. In the research literature the spelling epitalon and the variant epithalone both appear, while AEDG is the standard code used in peptide nomenclature.

Several names circulate for the same molecule, including epitalon, epithalone, epithalamin tetrapeptide, and the sequence code AEDG. A CAS registry number, 307297-39-8, is commonly cited for it, though catalogue entries should be checked against supplier documentation because mislabelled records occur. In its usual form the peptide carries free amino and carboxyl termini and is neither glycosylated nor lipidated. Researchers distinguish the defined tetrapeptide from epithalamin itself, a crude pineal preparation containing many peptides that is not chemically characterised.

Material supplied for laboratory use is normally a lyophilised white to off-white powder that dissolves readily in water and in isotonic saline. Lyophilised cakes are hygroscopic and should be equilibrated to room temperature before opening to limit condensation on the solid. Solutions are typically prepared at milligram-per-millilitre concentrations and divided into single-use aliquots, because repeated freeze–thaw cycles degrade short peptides. Aqueous solutions are far less stable than the dry powder, and identity is usually verified by mass spectrometry alongside purity estimation from reversed-phase high-performance liquid chromatography.

Supporting material

== Structure == Aggrecanase is a very large molecule. Its size is estimated to be around 2.5 million Daltons. The molecule is built from a core protein that weighs about 250 kilodaltons. The molecule is made of multiple subunits, each with a specific function. It has a signal sequence of about 170 amino acids in length. The purpose of this sequence is to direct the protein to the correct location of the cell. Another subunit is the pre domain, the metalloproteinase domain, which is around 230 amino acids in length. Its purpose is to keep the enzyme inactive until necessary. Another way the enzyme will remain inactive is in the absence of its catalytic region, which is dependent on zinc ion. Its purpose is to help bind the molecule and stabilize interactions. Attached to the core protein are glycosaminoglycans, a long chain of negatively charged polysaccharides. These glycosaminoglycans consist of chondroitin sulfate and keratan sulfate. The glycosaminoglycans being negatively charged, allow the aggrecan to hold large amounts of water. This is beneficial to the molecule because aggrecanase is a part of connective tissue, cartilage. The water allows the cartilage to better resist pressure when the joints it protects are compressed. This is because the water does not allow it to collapse, but instead spring back and maintain its structure.

While Operation Hooper was underway in late January 1988, Crocker relented to pressure and accepted Cuba as an equal partner in further peace talks. Castro agreed that he would not introduce extraneous issues to the agenda, such as Cuba–US relations, and that discussion of a phased troop withdrawal would extend to all Cuban military personnel stationed in Angola, including combat troops, logistical staff, and advisers. With Cuba's entry into the Brazzaville talks, its desire to shift its military involvement in Angola from a passive, defensive role to an offensive one intensified. Castro opted to escalate ground operations against the SADF, since he considered diplomatic progress impossible as long as South Africa still clung to the likelihood of a tactical victory. He retained a solely defensive posture at Cuito Cuanavale, keeping the SADF fixed in place, while carrying out his longstanding proposal to launch a flanking manoeuvre towards the South West African border. The new offensive would consist of a movement of Cuban forces in divisional strength west of the Cunene River. On 9 March, Castro ordered all Cuban troops massed at Lobito, which had grown to about 40,000 men, southward. He likened their movement to "a boxer who with his left hand blocks the blow [at Cuito Cuanavale] and with his right – strikes [in the west]".

=== Beyond sequence similarity === Proteins are known to conserve their tertiary structure more strongly than their amino acid sequences. Two distantly related proteins can have minimal or even undetectable sequence similarity, yet have highly similar folds that can be compared via structural alignment. Examples of these proteins used to be only discovered by experimental structural determination methods. Modern protein structure prediction methods such as AlphaFold2 allow possible homologs to be identified without wet lab work. RNA is also known to conserve tertiary structure more strongly than primary structure. RNA secondary structure prediction was found to be helpful in human-to-mouse comparison.

Sources: en.wikipedia.org

Notes from published material

limb muscle atrophy nonreactive degeneration of anterior horn cells degeneration and partial loss of pyramidal neurons of the motor cortex behavioral dysfunction conduction deficits in the central motor pathway neuropathological changes of motor cortex Betz cells There are reports that low BMAA concentrations can selectively kill cultured motor neurons from mouse spinal cords and produce reactive oxygen species. Scientists have also found that newborn rats treated with BMAA show a progressive neurodegeneration in the hippocampus, including intracellular fibrillar inclusions, and impaired learning and memory as adults. BMAA has been reported to be excreted into rodent breast milk, and subsequently transferred to the suckling offspring, suggesting mothers' and cows' milk might be other possible exposure routes.

Bernoulli's principle can be used to calculate the lift force on an airfoil, if the behaviour of the fluid flow in the vicinity of the foil is known. For example, if the air flowing past the top surface of an aircraft wing is moving faster than the air flowing past the bottom surface, then Bernoulli's principle implies that the pressure on the surfaces of the wing will be lower above than below. This pressure difference results in an upwards lifting force. Whenever the distribution of speed past the top and bottom surfaces of a wing is known, the lift forces can be calculated (to a good approximation) using Bernoulli's equations, which were established by Bernoulli over a century before the first man-made wings were used for the purpose of flight. The basis of a carburetor used in many reciprocating engines is a throat in the air flow to create a region of low pressure to draw fuel into the carburetor and mix it thoroughly with the incoming air. The low pressure in the throat can be explained by Bernoulli's principle, where air in the throat is moving at its fastest speed and therefore it is at its lowest pressure. The carburetor may or may not use the difference between the two static pressures which result from the Venturi effect on the air flow in order to force the fuel to flow, and as a basis a carburetor may use the difference in pressure between the throat and local air pressure in the float bowl, or between the throat and a Pitot tube at the air entry. An injector on a steam locomotive or a static boiler.

Alzheimer's disease (AD) can be definitively diagnosed only with histopathological findings; in the absence of autopsy or brain biopsy, clinical diagnoses of AD are "possible" or "probable", based on other findings. Up to 23% of those clinically diagnosed with AD may be misdiagnosed and may have pathology suggestive of another condition with symptoms that mimic those of AD.

Sources: en.wikipedia.org

Frequently asked questions

What is epitalon made of?

It is a synthetic tetrapeptide built from alanine, glutamate, aspartate and glycine. The four residues are joined by standard peptide bonds, giving a linear chain rather than a branched structure.

Why is it called epitalon?

The name derives from epithalamin, a pineal gland extract studied in the former Soviet Union. Researchers proposed that short fragments of that extract carried the biological activity of interest.

Is epitalon approved for medical use?

No major regulatory agency has approved it as a medicine. It is handled as a research chemical, and products sold under this name are not standardised drugs with defined clinical labelling.

What is epitalon?

Epitalon is a synthetic four-amino-acid peptide with the sequence alanine–glutamate–aspartate–glycine, also written AEDG. It was developed in Russian gerontology research and is studied for proposed effects on telomerase, melatonin regulation, and neuroendocrine function. It is not an approved pharmaceutical in the United States or the European Union.

Network